biomarkers for disease activity

A forum to discuss research on the origins of MS and its development.

biomarkers for disease activity

Postby frodo » Sun Oct 08, 2017 5:34 am

Fluid biomarkers for disease activity in multiple sclerosis ... 8517736151

Multiple sclerosis (MS) is an inflammatory and degenerative central nervous system (CNS) disease. There is accumulating evidence that the inflammatory activity is responsible for nervous tissue degeneration and disability development, especially during the early phases of MS.

The rate of inflammation or disease activity is reflected in relapses and lesion formation on magnetic resonance imaging (MRI) and subsequently in residual disability and atrophy development. Experience from two decades of therapeutic interventions in relapsing–remitting (RR) MS shows that immunomodulatory and immunosuppressive drugs reduce disease activity, and there seems to be an effect also on the rate of disease progression. Thus, disease-modifying therapies (DMTs) reduce CNS inflammation and change the clinical course and prognosis of MS.

Currently, patient assessment for treatment decisions in clinical practice is based almost entirely on clinical and MRI measures. However, to predict disability development, degeneration and therapeutic response, the development of biomarkers that reflect disease activity, meaning inflammatory activity and the intensity of the axonal injury process, is essential.
User avatar
Family Elder
Posts: 902
Joined: Wed Dec 02, 2009 4:00 pm


Return to MS Etiology and Pathogenesis


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service